PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer

References

• Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21:37–9. doi:10.1038/s41568-020-00308-y.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025.
   PubMed Web of Science ®Google Scholar
• Cocetta V, Ragazzi E, Montopoli M. Links between cancer metabolism and cisplatin resistance. Int Rev Cell Mol Biol. 2020;354:107–164. doi:10.1016/bs.ircmb.2020.01.005.
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–584. doi:10.1038/nrc2167.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141–148. doi:10.1093/annonc/mdu472.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. doi:10.1056/NEJMoa073149.
   PubMed Web of Science ®Google Scholar
• Chinen T, Sasabuchi Y, Matsui H, Yamaguchi H, Yasunaga H. Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study. BMC Cancer. 2022;22(1):460. doi:10.1186/s12885-022-09581-6.
   PubMed Web of Science ®Google Scholar
• Huang J, Zhao Y, Xu Y, Zhu Y, Huang J, Liu Y, Zhao L, Li Z, Liu H, Wang Q-L, et al. Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: a meta-analysis of randomized controlled trials. Oncotarget. 2016;7(23):34824–34831. doi:10.18632/oncotarget.9189.
   PubMedGoogle Scholar
• Zhang F, Zhang Y, Jia Z, Wu H, Gu K. Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer: a meta-analysis. J Cancer. 2019;10(8):1923–1929. doi:10.7150/jca.28896.
   PubMed Web of Science ®Google Scholar
• Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14:50–55. doi:10.1007/s10120-011-0007-7.
   PubMed Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482–491. doi:10.1038/onc.2009.356.
   PubMed Web of Science ®Google Scholar
• Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L, et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology. 2020;9:1703449. doi:10.1080/2162402X.2019.1703449.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1:179–188. doi:10.4161/onci.1.2.19026.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8:e000337. doi:10.1136/jitc-2019-000337.
   PubMed Web of Science ®Google Scholar
• Kepp O, Bezu, L., Yamazaki, T., Di Virgilio, F., Smyth, M. J., Kroemer, G., & Galluzzi, L. ATP and cancer immunosurveillance. EMBO J. 2021;40:e108130. doi:10.15252/embj.2021108130.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487–500. doi:10.1038/s41590-022-01132-2.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51–72. doi:10.1146/annurev-immunol-032712-100008.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Kepp O. Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients. Oncoimmunology. 2021;10(1):2005859. doi:10.1080/2162402X.2021.2005859.
   PubMed Web of Science ®Google Scholar
• Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev. 2013;24(4):311–318. doi:10.1016/j.cytogfr.2013.05.001.
   PubMed Web of Science ®Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301–1309. doi:10.1038/nm.3708.
   PubMed Web of Science ®Google Scholar
• Sprooten J, Garg AD. Type I interferons and endoplasmic reticulum stress in health and disease. Int Rev Cell Mol Biol. 2020;350:63–118. doi:10.1016/bs.ircmb.2019.10.004.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Kirchmair A, Sato A, Buqué A, Rybstein M, Petroni G, Bloy N, Finotello F, Stafford L, Navarro Manzano E, et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat Immunol. 2020;21(10):1160–1171. doi:10.1038/s41590-020-0751-0.
   PubMed Web of Science ®Google Scholar
• Workenhe ST, Pol J, Kroemer G. Tumor-intrinsic determinants of immunogenic cell death modalities. Oncoimmunology. 2021;10(1):1893466. doi:10.1080/2162402X.2021.1893466.
   PubMed Web of Science ®Google Scholar
• Xin M, Lin D, Yan N, Li H, Li J, Huang Z. Oxaliplatin facilitates tumor-infiltration of T cells and natural-killer cells for enhanced tumor immunotherapy in lung cancer model. Anticancer Drugs. 2022;33(2):117–123. doi:10.1097/CAD.0000000000001248.
   PubMed Web of Science ®Google Scholar
• Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. doi:10.1038/s41467-020-17670-y.
   PubMed Web of Science ®Google Scholar
• Husstegge M, Hoang NA, Rebstock J, Monecke A, Gockel I, Weimann A, Schumacher G, Bechmann I, Lordick F, Kallendrusch S, et al. PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. Oncoimmunology. 2021;10(1):1960729. doi:10.1080/2162402X.2021.1960729.
   PubMed Web of Science ®Google Scholar
• Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27(2):212–224. doi:10.1038/s41591-021-01233-9.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–741. doi:10.1038/s41571-020-0413-z.
   PubMed Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44(2):343–354. doi:10.1016/j.immuni.2015.11.024.
   PubMed Web of Science ®Google Scholar
• Zhu H, Shan, Y., Ge, K., Lu, J., Kong, W., & Jia, C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol (Dordr). 2020;43(6):1203–1214. doi:10.1007/s13402-020-00552-2.
   PubMed Web of Science ®Google Scholar
• Levesque S, Le Naour, J., Pietrocola, F., Paillet, J., Kremer, M., Castoldi, F., & Pol, J. G. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. Oncoimmunology. 2019;8(11):e1657375. doi:10.1080/2162402X.2019.1657375.
   PubMed Web of Science ®Google Scholar
• Sun F, Cui L, Li T, Chen S, Song J, Li D. Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma. journal of Receptors and Signal transduction. 2019;39(3):208–214. doi:10.1080/10799893.2019.1655050.
   PubMed Web of Science ®Google Scholar
• Song W, Shen L, Wang Y, Liu Q, Goodwin TJ, Li J, Dorosheva O, Liu T, Liu R, Huang L, et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun. 2018;9(1):2237. doi:10.1038/s41467-018-04605-x.
   PubMed Web of Science ®Google Scholar
• Wang W, Wu L, Zhang J, Wu H, Han E, Guo Q. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. Biochem Biophys Res Commun. 2017;487(1):1–7. doi:10.1016/j.bbrc.2016.12.180.
   PubMed Web of Science ®Google Scholar
• Maharjan R, Choi JU, Kweon S, Pangeni R, Lee NK, Park SJ, Chang K-Y, Park JW, Byun Y. A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy. Biomaterials. 2022;281:121334. doi:10.1016/j.biomaterials.2021.121334.
   PubMed Web of Science ®Google Scholar
• Limagne E, Thibaudin M, Nuttin L, Spill A, Derangère V, Fumet J-D, Amellal N, Peranzoni E, Cattan V, Ghiringhelli F, et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res. 2019;7(12):1958–1969. doi:10.1158/2326-6066.CIR-19-0228.
   PubMed Web of Science ®Google Scholar
• Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, Serre L, Jordheim LP, Matera EL, Dumontet C, et al. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018;9:2100. doi:10.3389/fimmu.2018.02100.
   PubMed Web of Science ®Google Scholar
• Kim W, Chu TH, Nienhüser H, Jiang Z, Del Portillo A, Remotti HE, White RA, Hayakawa Y, Tomita H, Fox JG, et al. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology. 2021;160(3):781–796. doi:10.1053/j.gastro.2020.10.036.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Buque A, Ames TD, Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020;9(1):1721810. doi:10.1080/2162402X.2020.1721810.
   PubMed Web of Science ®Google Scholar
• Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun. 2019;10(1):1486. doi:10.1038/s41467-019-09415-3.
   PubMed Web of Science ®Google Scholar
• Petrazzuolo A, Perez-Lanzon M, Liu P, Maiuri MC, Kroemer G. Crizotinib and ceritinib trigger immunogenic cell death via on-target effects. Oncoimmunology. 2021;10(1):1973197. doi:10.1080/2162402X.2021.1973197.
   PubMed Web of Science ®Google Scholar
• Petrazzuolo A, Perez-Lanzon M, Martins I, Liu P, Kepp O, Minard-Colin V, Maiuri MC, Kroemer G. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. Cell Death Dis. 2021;12(8):713. doi:10.1038/s41419-021-03997-x.
   PubMed Web of Science ®Google Scholar
• Hossain DMS, Javaid S, Cai M, Zhang C, Sawant A, Hinton M, Sathe M, Grein J, Blumenschein W, Pinheiro EM, et al. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. J Clin Invest. 2018;128(2):644–654. doi:10.1172/JCI94586.
   PubMed Web of Science ®Google Scholar
• Xie W, Forveille S, Iribarren K, Sauvat A, Senovilla L, Wang Y, Humeau J, Perez-Lanzon M, Zhou H, Martínez-Leal JF, et al. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. Oncoimmunology. 2019;8(11):e1656502. doi:10.1080/2162402X.2019.1656502.
   PubMed Web of Science ®Google Scholar
• Kepp O, Zitvogel L, Kroemer G. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. Oncoimmunology. 2020;9(1):1795995. doi:10.1080/2162402X.2020.1795995.
   PubMed Web of Science ®Google Scholar
• Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer. 2018;118(10):1329–1336. doi:10.1038/s41416-018-0076-z.
   PubMed Web of Science ®Google Scholar
• Xie W, Mondragón L, Mauseth B, Wang Y, Pol J, Lévesque S, Zhou H, Yamazaki T, Eksteen JJ, Zitvogel, et al. Tumor lysis with LTX-401 creates anticancer immunity. Oncoimmunology. 2019;8(7):1594555. doi:10.1080/2162402X.2019.1594555.
   PubMed Web of Science ®Google Scholar
• Bezu L, Wu Chuang A, Sauvat A, Humeau J, Xie W, Cerrato G, Liu P, Zhao L, Zhang S, Le Naour J, et al. Local anesthetics elicit immune-dependent anticancer effects. J Immunother Cancer. 2022;10(4):e004151. doi:10.1136/jitc-2021-004151.
   PubMed Web of Science ®Google Scholar
• Chen G, Chen Z, Wen D, Wang Z, Li H, Zeng Y, Dotti G, Wirz RE, Gu Z. Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy. Proc Natl Acad Sci U S A. 2020;117(7):3687–3692. doi:10.1073/pnas.1917891117.
   PubMed Web of Science ®Google Scholar
• Lin A, Gorbanev Y, De Backer J, Van Loenhout J, Van Boxem W, Lemière F, Cos P, Dewilde S, Smits E, Bogaerts A, et al. Non-Thermal Plasma as a Unique Delivery System of Short-Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells. Adv Sci (Weinh). 2019;6(6):1802062. doi:10.1002/advs.201802062.
   PubMedGoogle Scholar
• Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, Buczkowski KA, Grant AK, Ullas S, Rhee K, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016;1(9):e87415. doi:10.1172/jci.insight.87415.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xie W, Zhang Y, Dong X, Liu C, Yi J, Zhang S, Wen C, Zheng L, Wang H, et al. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Cancer Gene Ther. 2022;29(5):456–465. doi:10.1038/s41417-021-00389-3.
   PubMed Web of Science ®Google Scholar
• Humeau J, Sauvat A, Cerrato G, Xie W, Loos F, Iannantuoni F, Bezu L, Lévesque S, Paillet J, Pol J, et al. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Mol Med. 2020;12(5):e11622. doi:10.15252/emmm.201911622.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Kepp O. Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade. Oncoimmunology. 2021;10(1996686). doi:10.1080/2162402X.2021.1996686.
   Google Scholar
• Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol (Dordr). 2020;43(6):1203–1214. doi:10.1007/s13402-020-00552-2.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, Garrison SM, Specht JM, Lee SM, Amezquita RA, et al. Immunogenic Chemotherapy Enhances Recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell. 2021;39(2):193–208 e110. doi:10.1016/j.ccell.2020.11.005.
   PubMed Web of Science ®Google Scholar
• Siew YY, Soek-Ying Neo, Hui-Chuing Yew, Shun-Wei Lim, Yi-Cheng Ng,Si-Min Lew, Wei-Guang Seetoh, See-Voon Seow, and Hwee-Ling Koh. Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity. Int Immunol. 2015;27(12):621–632. doi:10.1093/intimm/dxv041.
   PubMed Web of Science ®Google Scholar
• Gou HF, Zhou L, Huang J, Chen XC. Intraperitoneal oxaliplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer. Mol Med Rep. 2018;18(2):2335–2341. doi:10.3892/mmr.2018.9219.
   PubMed Web of Science ®Google Scholar
• Stojanovska V, Prakash M, McQuade R, Fraser S, Apostolopoulos V, Sakkal S, Nurgali K. Oxaliplatin treatment alters systemic immune responses. Biomed Res Int. 2019;2019:4650695. doi:10.1155/2019/4650695.
   PubMed Web of Science ®Google Scholar
• Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, et al. Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. Br J Cancer. 2018;118(10):1322–1328. doi:10.1038/s41416-018-0085-y.
   PubMed Web of Science ®Google Scholar
• Xu J, Xu N, Bai Y, Liu R, Mao C, Sui H, Wang X, Jiang Q, Dou Y. Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial. Oncoimmunology. 2020;10(1):1864908. doi:10.1080/2162402X.2020.1864908.
   PubMed Web of Science ®Google Scholar
• Zhang AZ, Yuan X, Liang WH, Zhang HJ, Li Y, Xie YF, Li JF, Jiang CH, Li FP, Shen XH, et al. Immune infiltration in gastric cancer microenvironment and its clinical significance. Front Cell Dev Biol. 2021;9:762029. doi:10.3389/fcell.2021.762029.
   PubMed Web of Science ®Google Scholar
• Li C, Pan J, Jiang Y, Yu Y, Jin Z, Chen X. Characteristics of the immune cell infiltration landscape in gastric cancer to assistant immunotherapy. Front Genet. 2021;12:793628. doi:10.3389/fgene.2021.793628.
   PubMed Web of Science ®Google Scholar
• Xing X, Shi J, Jia Y, Dou Y, Li Z, Dong B, Guo T, Cheng X, Li X, Du H, et al. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis. J Immunother Cancer. 2022;10(3):e003984. doi:10.1136/jitc-2021-003984.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. doi:10.1016/S0140-6736(21)00797-2.
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang Y-J, Fuchs C, Wyrwicz L, Lee K-W, Kudaba I, Garrido M, Chung HC, Lee J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–1580. doi:10.1001/jamaoncol.2020.3370.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–730. doi:10.1038/s41586-021-04161-3.
   PubMed Web of Science ®Google Scholar